
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc. is positioned for potential growth, particularly driven by the positive placement and utilization trends of its sequencing platforms, including Revio and Onso. The company's strong organic growth profile is complemented by strategic acquisitions, enhancing its market position and capabilities in genetic analysis. Despite a cautious approach in its 2024 guidance amid a challenging macroeconomic environment, management's optimistic outlook for a return to growth this year highlights confidence in the company's trajectory.
Bears say
Pacific Biosciences of California Inc faces significant headwinds that could jeopardize its financial outlook, particularly with concerns surrounding stagnant utilization rates and potential weakening demand for new instruments, which threaten its 2026 financial targets. Additionally, ongoing demand weakness in critical markets like China, coupled with tightened research budgets and reduced funding in the biotech sector, further constrains customer purchasing power and adversely impacts potential revenue. Finally, the risk of losing market share to competitors developing superior products adds to the uncertainty surrounding the company's future financial performance.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares